These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16403626)

  • 1. Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
    Li Q; Li T; Zhu GD; Gong J; Claibone A; Dalton C; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Bauch JL; Marsh KC; Bouska JJ; Arries S; De Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1679-85. PubMed ID: 16403626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
    Li Q; Woods KW; Thomas S; Zhu GD; Packard G; Fisher J; Li T; Gong J; Dinges J; Song X; Abrams J; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Des Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
    Bioorg Med Chem Lett; 2006 Apr; 16(7):2000-7. PubMed ID: 16413780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.
    Donald A; McHardy T; Rowlands MG; Hunter LJ; Davies TG; Berdini V; Boyle RG; Aherne GW; Garrett MD; Collins I
    J Med Chem; 2007 May; 50(10):2289-92. PubMed ID: 17451235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of inhibitors of protein kinase B using fragment-based lead discovery.
    Saxty G; Woodhead SJ; Berdini V; Davies TG; Verdonk ML; Wyatt PG; Boyle RG; Barford D; Downham R; Garrett MD; Carr RA
    J Med Chem; 2007 May; 50(10):2293-6. PubMed ID: 17451234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
    Lin X; Murray JM; Rico AC; Wang MX; Chu DT; Zhou Y; Del Rosario M; Kaufman S; Ma S; Fang E; Crawford K; Jefferson AB
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4163-8. PubMed ID: 16765046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants.
    Breitenlechner CB; Friebe WG; Brunet E; Werner G; Graul K; Thomas U; Künkele KP; Schäfer W; Gassel M; Bossemeyer D; Huber R; Engh RA; Masjost B
    J Med Chem; 2005 Jan; 48(1):163-70. PubMed ID: 15634010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azole-based inhibitors of AKT/PKB for the treatment of cancer.
    Zeng Q; Allen JG; Bourbeau MP; Wang X; Yao G; Tadesse S; Rider JT; Yuan CC; Hong FT; Lee MR; Zhang S; Lofgren JA; Freeman DJ; Yang S; Li C; Tominey E; Huang X; Hoffman D; Yamane HK; Fotsch C; Dominguez C; Hungate R; Zhang X
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1559-64. PubMed ID: 20137943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AKT crystal structure and AKT-specific inhibitors.
    Kumar CC; Madison V
    Oncogene; 2005 Nov; 24(50):7493-501. PubMed ID: 16288296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.
    Woods KW; Fischer JP; Claiborne A; Li T; Thomas SA; Zhu GD; Diebold RB; Liu X; Shi Y; Klinghofer V; Han EK; Guan R; Magnone SR; Johnson EF; Bouska JJ; Olson AM; de Jong R; Oltersdorf T; Luo Y; Rosenberg SH; Giranda VL; Li Q
    Bioorg Med Chem; 2006 Oct; 14(20):6832-46. PubMed ID: 16843670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B.
    Collins I; Caldwell J; Fonseca T; Donald A; Bavetsias V; Hunter LJ; Garrett MD; Rowlands MG; Aherne GW; Davies TG; Berdini V; Woodhead SJ; Davis D; Seavers LC; Wyatt PG; Workman P; McDonald E
    Bioorg Med Chem; 2006 Feb; 14(4):1255-73. PubMed ID: 16249095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics.
    Zeng Q; Bourbeau MP; Wohlhieter GE; Yao G; Monenschein H; Rider JT; Lee MR; Zhang S; Lofgren J; Freeman D; Li C; Tominey E; Huang X; Hoffman D; Yamane H; Tasker AS; Dominguez C; Viswanadhan VN; Hungate R; Zhang X
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1652-6. PubMed ID: 20137932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.
    Thomas SA; Li T; Woods KW; Song X; Packard G; Fischer JP; Diebold RB; Liu X; Shi Y; Klinghofer V; Johnson EF; Bouska JJ; Olson A; Guan R; Magnone SR; Marsh K; Luo Y; Rosenberg SH; Giranda VL; Li Q
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3740-4. PubMed ID: 16678413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
    Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.
    Rhodes N; Heerding DA; Duckett DR; Eberwein DJ; Knick VB; Lansing TJ; McConnell RT; Gilmer TM; Zhang SY; Robell K; Kahana JA; Geske RS; Kleymenova EV; Choudhry AE; Lai Z; Leber JD; Minthorn EA; Strum SL; Wood ER; Huang PS; Copeland RA; Kumar R
    Cancer Res; 2008 Apr; 68(7):2366-74. PubMed ID: 18381444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors.
    Kendall JD; O'Connor PD; Marshall AJ; Frédérick R; Marshall ES; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
    Bioorg Med Chem; 2012 Jan; 20(1):69-85. PubMed ID: 22177405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.
    Ashwell MA; Lapierre JM; Brassard C; Bresciano K; Bull C; Cornell-Kennon S; Eathiraj S; France DS; Hall T; Hill J; Kelleher E; Khanapurkar S; Kizer D; Koerner S; Link J; Liu Y; Makhija S; Moussa M; Namdev N; Nguyen K; Nicewonger R; Palma R; Szwaya J; Tandon M; Uppalapati U; Vensel D; Volak LP; Volckova E; Westlund N; Wu H; Yang RY; Chan TC
    J Med Chem; 2012 Jun; 55(11):5291-310. PubMed ID: 22533986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt.
    Zhu GD; Gong J; Gandhi VB; Woods K; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Stoll VS; Mamo M; Li Q; Rosenberg SH; Giranda VL
    Bioorg Med Chem; 2007 Mar; 15(6):2441-52. PubMed ID: 17258463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The involvement of phosphatidylinositol 3-kinase in gonadotropin-releasing hormone-induced gonadotropin alpha- and FSHbeta-subunit genes expression in clonal gonadotroph LbetaT2 cells.
    Mutiara S; Kanasaki H; Harada T; Oride A; Miyazaki K
    Mol Cell Endocrinol; 2008 Feb; 283(1-2):1-11. PubMed ID: 18206295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and structure based optimization of novel Akt inhibitors.
    Lippa B; Pan G; Corbett M; Li C; Kauffman GS; Pandit J; Robinson S; Wei L; Kozina E; Marr ES; Borzillo G; Knauth E; Barbacci-Tobin EG; Vincent P; Troutman M; Baker D; Rajamohan F; Kakar S; Clark T; Morris J
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3359-63. PubMed ID: 18456494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional characterization of peanut serine/threonine/tyrosine protein kinase: molecular docking and inhibition kinetics with tyrosine kinase inhibitors.
    Rudrabhatla P; Rajasekharan R
    Biochemistry; 2004 Sep; 43(38):12123-32. PubMed ID: 15379551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.